A detailed history of Spire Wealth Management transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Spire Wealth Management holds 380 shares of ALNY stock, worth $93,267. This represents 0.0% of its overall portfolio holdings.

Number of Shares
380
Previous 377 0.8%
Holding current value
$93,267
Previous $91,000 14.29%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$233.81 - $287.01 $701 - $861
3 Added 0.8%
380 $104,000
Q2 2024

Jul 31, 2024

SELL
$143.31 - $247.0 $29,521 - $50,882
-206 Reduced 35.33%
377 $91,000
Q1 2024

Apr 24, 2024

BUY
$146.51 - $198.2 $439 - $594
3 Added 0.52%
583 $87,000
Q3 2023

Nov 08, 2023

SELL
$170.77 - $211.65 $170 - $211
-1 Reduced 0.17%
580 $102,000
Q2 2023

Aug 09, 2023

SELL
$185.01 - $212.05 $58,278 - $66,795
-315 Reduced 35.16%
581 $110,000
Q1 2023

May 09, 2023

BUY
$182.66 - $235.53 $40,915 - $52,758
224 Added 33.33%
896 $179,000
Q4 2022

Feb 03, 2023

SELL
$185.53 - $241.31 $2,411 - $3,137
-13 Reduced 1.9%
672 $160,000
Q3 2022

Nov 07, 2022

SELL
$138.54 - $232.0 $34,219 - $57,304
-247 Reduced 26.5%
685 $137,000
Q2 2022

Jul 22, 2022

SELL
$120.42 - $169.29 $50,335 - $70,763
-418 Reduced 30.96%
932 $136,000
Q1 2022

Apr 18, 2022

BUY
$127.18 - $173.91 $112,172 - $153,388
882 Added 188.46%
1,350 $221,000
Q4 2021

Jan 14, 2022

BUY
$159.56 - $209.29 $1,436 - $1,883
9 Added 1.96%
468 $81,000
Q2 2021

Jul 26, 2021

BUY
$128.63 - $176.89 $2,829 - $3,891
22 Added 5.03%
459 $78,000
Q1 2021

May 21, 2021

BUY
$126.83 - $175.69 $55,424 - $76,776
437 New
437 $62,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.2B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Spire Wealth Management Portfolio

Follow Spire Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Spire Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Spire Wealth Management with notifications on news.